Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Expert Opinion on Pharmacotherapy|July 18, 2022
Tivozanib for the treatment of advanced renal cell carcinomaJonathan Chatzkel, Brian Ramnaraign, Guru Sonpavde
Annals of the American Thoracic Society|June 24, 2014
Expiratory air trapping on thoracic computed tomography. A diagnostic subclassificationWallace T Miller, Jonathan Chatzkel, Michael G Hewitt
European Urology Focus|July 27, 2025
Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic TherapiesJonathan Chatzkel, Joshua Linscott, G Daniel Grass, et al.
Research and Reports in Urology|July 29, 2024
Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the ClinicJonathan Chatzkel, Mayer Fishman, Brian Ramnaraign, et al.
Future Science OA|January 10, 2020
Circulating tumor cells and γH2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patientsJonathan Chatzkel, Jesse Mocha, Johnna Smith, et al.
Clinical Genitourinary Cancer|March 7, 2022
Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal CancerJonathan Chatzkel, Michael J Schell, Jad Chahoud, et al.
Head and Neck Pathology|December 28, 2016
Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell CarcinomaJonathan Chatzkel, James S Lewis, Jessica C Ley, et al.
European Urology|June 26, 2026
Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management ImplicationsCan Aydogdu, Laura Bukavina, Liang Cheng, et al.
Nature Communications|May 25, 2026
Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trialJeffrey S Johnson, Justin W Miller, Firas Hatoum, et al.
Pageof 1